Main points of investment:
Develop a professional monitoring tool iHealthPro product line for doctors to speed up the opening of B2B channels. The iHealthPro product line being developed by the company is a monitoring tool for doctors to collect data such as 24-inch blood pressure, upper and lower extremity blood pressure, ECG, blood oxygen and so on, so that doctors can obtain more clinical guiding data. IHealth business model has expanded from B2C to B2B, from providing intelligent hardware for personal health management to providing intelligent diagnosis and treatment service tools for personnel related to industrial medical institutions, the company strives to make a breakthrough in 2015 in not cooperating with industrial medical institutions in China, Europe and the United States.
The effect of cooperation with XIAOMI began to show, Rice Noodle Festival iHealth intelligent sphygmomanometer sold more than 16000 sets on the same day, and the follow-up popular style is in research. On May 8, 2015, the sales of iHealth intelligent sphygmomanometer at XIAOMI's fifth anniversary "Rice Noodle Festival" exceeded 16000, creating a record for the sales of inferior sphygmomanometer products. On Mother's Day, the intelligent sphygmomanometer without the cooperation of XIAOMI launched an upgraded version, which included raising the original battery capacity to 400mA to 2200 Ma for five months on a single charge, upgrading the PCB motherboard to enhance stability, upgrading the original interface to the standard MicroUSB interface and other six major functions. The second cooperative product of XIAOMI is under research in an orderly manner.
A number of new products are being recruited and are expected to be available by the end of this year. The products recruiting candidates are intelligent blood glucose meter Ambient universal version, intelligent sphygmomanometer universal version, intelligent pulse oximeter. With the expansion of the product line, the number of users and frequency of use will increase, and the value of healthy big data will be highlighted.
Maintain the "highly recommended" rating. The operation idea of the company's intelligent medical equipment ihealth series products is gradually clear, first with intelligent hardware as the entrance to do health management, and then based on health big data to do medical services. It is estimated that the EPS in 15-17 years will be-0.20,0.01,0.07 yuan respectively, and the target market value in the next 6-12 months will be 20 billion yuan, raising the target price to 52.40 yuan.
Risk Tip: the low expected risk of ihealth series promotion, the risk of continued increase in sales expenses and R & D expenses leading to a persistently low level of profitability
